Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nanobiotix S.A.NASDAQ: NBTX

Research & Development · Q4 FY2025 · quarter ended Dec 2025

Research & development declines year over year

Q4 FY2025 research & development of €8.59M fell 53.7% year over year. Over 3 fiscal years it compounded at -10.9% a year.

Context

  • Research & development amounted to 78.0% of revenue in FY2025.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€8.59M— QoQ
Last fiscal yearDec 2025
€23.12M-43.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.7%——
1 year-43.0%——
3-year CAGR-10.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
23.12M EUR
Year-over-year change
-43.0%
4-year CAGR
-6.6%

Research & Development vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.0% is the lowest of 11, against a peer median of +30.0%.
  • Research & development amounts to 78.0% of revenue for NBTX, versus a peer median of 128.0%.
NBTX Competitors
Research & Development for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KURAKura Oncology, Inc.LTM Mar 2026$260.36M USD+37.3%+39.3%363.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M USD+3.7%+29.7%117.9%
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M USD+33.2%-5.7%138.2%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$129.68M USD+5.2%+71.4%—
TYRATyra Biosciences, Inc.LTM Mar 2026$111.3M USD+26.9%+33.8%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$68M USD+23.2%+5.9%29.9%
CADLCandel Therapeutics, Inc.LTM Mar 2026$36.32M USD+88.9%+13.6%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$30.06M USD-37.6%-19.5%—
NBTXNanobiotix S.A.FY2025€23.12M EUR-43.0%-10.9%78.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M USD+102.3%+57.1%—
NVCTNuvectis Pharma, Inc.LTM Mar 2026$18.58M USD+33.3%+11.1%—
Peer median (excluding NBTX) —+30.0%+21.7%128.0%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.65M4.78M36.21M(7.19M)29.64M
Cost of Revenue00000
Gross Profit2.65M4.78M36.21M(7.19M)29.64M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development30.38M32.64M38.4M40.54M23.12M
Selling, General & Admin19.43M17.86M22.05M20.53M20.22M
Operating Expenses55.23M51.48M62.99M61.2M40.46M
Depreciation & Amortization1.56M1.5M551K592K1.5M
EBITDA(45.61M)(44.22M)(23.69M)(67.67M)(12.07M)
EBITDA Margin-1722.9%-925.8%-65.4%941.1%-40.7%
Operating Income(52.58M)(46.7M)(26.78M)(68.39M)(10.82M)
Operating Margin-1986.4%-977.8%-74.0%951.2%-36.5%
Interest Income0256K1.22M2.63M985K
Interest Expense699.49K5.84M7.98M8.09M10.4M
Other Income / Expenses5.58M(10.33M)(12.8M)361K(13.14M)
Income Before Tax(47M)(57.03M)(39.58M)(68.03M)(23.96M)
Pre-Tax Margin-1775.5%-1194.1%-109.3%946.2%-80.8%
Income Tax Expense5K10K120K101K3K
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Net Margin-1775.7%-1194.3%-109.6%947.6%-80.8%
EPS (Basic)(1.35)(1.64)(1.08)(1.44)(0.50)
EPS (Diluted)(1.35)(1.64)(1.08)(1.44)(0.50)
Weighted Avg Shares34.73M34.85M36.76M47.27M47.82M
Weighted Avg Shares (Diluted)34.73M34.85M36.93M47.27M47.82M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.